Fujian Cancer Hospital: Stomach Neoplasms trials

The registry lists 19 Stomach Neoplasms studies with Fujian Cancer Hospital as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 12Phase 3 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical TrialRecruitingNCT07142122Not applicable
• Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06793917Phase 3
• Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingNCT06197438Phase 2
• Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric CancerNot yet recruitingNCT05751265Phase 2
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
• Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
• A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal TumorsActive, not recruitingNCT07104877Not applicable
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
• Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric CancerStatus unknownNCT05035446Phase 3
• POF Versus FOLFOX Plus IP Paclitaxel in AGCStatus unknownNCT04155671Phase 2
• Neoadjuvant POF in the Treatment of Locally Advanced Gastric CancerStatus unknownNCT04149015Phase 2
• Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy RegimensStatus unknownNCT04089657Phase 2
• A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric CancerStatus unknownNCT03788226Phase 3
• Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric CancerStatus unknownNCT03137004Phase 2
• mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJAStatus unknownNCT03045770Not applicable
• Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2
• POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGCCompletedNCT02845908Phase 2
• Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric CancerStatus unknownNCT02697838Phase 2
• Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT02365896Not applicable